India’s Leap Into Digitized Pharmacovigilance Systems

India, one of the world’s largest pharmaceutical producers, plays a critical role in global drug supply and vaccine distribution. With increasing clinical trials, mass immunization programs, and expanding healthcare access, the need for robust pharmacovigilance (PV) systems has never been greater.

Traditional, paper-based reporting systems are no longer sufficient.

What is digital pharmacovigilance in India?
Digital pharmacovigilance in India refers to the use of online platforms, mobile tools, and integrated systems like Vigiflow and e-AEFI to monitor drug and vaccine safety in real time, improving reporting, analysis, and regulatory decision-making.

India is now undergoing a major transformation toward digitized pharmacovigilance systems, enabling:

• Real-time adverse event monitoring 
• Faster regulatory decision-making 
• Improved patient safety outcomes 

Background: Why Digitization Is Needed

Several factors have accelerated the shift toward digital PV systems:

• Explosion in drug usage and clinical trials 
• Increasing complexity of safety data 
• Need for rapid signal detection 
• Demand for global regulatory alignment 

The COVID-19 pandemic further highlighted the importance of real-time safety monitoring at scale.

Key Drivers for Digital Pharmacovigilance

1. Mass Vaccination Programs

Large-scale campaigns like COVID-19 required:

• Real-time tracking of Adverse Events Following Immunization (AEFI) 
• Rapid signal detection and response 

Digital tools became essential for managing high-volume data.

2. Global Regulatory Expectations

Organizations such as the World Health Organization and the U.S. Food and Drug Administration emphasize:

• Transparency in safety reporting 
• Timely data sharing 
• Strong pharmacovigilance systems 

3. Growth in Clinical Trials

India’s expanding clinical research ecosystem demands:

• Efficient local safety monitoring 
• Faster case processing and reporting 

4. National Digital Health Initiatives

Government programs such as:

• Digital India 
• Ayushman Bharat 

are driving integration of digital health infrastructure, including pharmacovigilance.

Key Digital Pharmacovigilance Developments

a. Integrated Adverse Event Reporting Systems

The Central Drugs Standard Control Organization and Indian Pharmacopoeia Commission have developed:

• Online ADR reporting portals 
• Mobile applications for healthcare professionals and patients 
• SMS-based reporting systems for rural accessibility 

These systems improve reporting accessibility and speed.

b. PvPI’s Vigiflow Integration

Under the Pharmacovigilance Programme of India (PvPI), IPC manages integration with:

• VigiFlow 

Key Capabilities

• Online case intake and management 
• Signal detection and analysis 
• Data sharing with global safety databases 

India contributes to VigiBase, enhancing global drug safety monitoring.

c. e-AEFI Module (MoHFW & WHO India)

The Ministry of Health & Family Welfare (MoHFW), in collaboration with WHO India, launched:

• Digital AEFI tracking systems 
• Integration with vaccination platforms like CoWIN 

Benefits

• Faster case investigation 
• Improved root cause analysis 
• Real-time vaccine safety tracking 

d. AI & Automation Pilots

Emerging technologies are being explored:

• Artificial Intelligence (AI) for signal detection 
• Automation of case processing 
• Natural Language Processing (NLP) for data extraction 

Currently in pilot stages, with growing adoption by pharma companies and CROs.

Key Agencies and Their Roles

Pharmacovigilance Ecosystem in India

Outcomes & Benefits of Digital PV

Key Achievements

• Expansion of 500+ Adverse Drug Reaction Monitoring Centres (AMCs) 
• Increased reporting rates 
• Faster case processing and triage 
• Enhanced global collaboration 

Benefits of Digitized PV

Challenges in Implementation

Despite progress, several challenges remain:

1. Underreporting

• Many adverse events still go unreported 

2. Awareness Gaps

• Limited training among healthcare professionals 

3. Infrastructure Limitations

• Rural and remote areas face connectivity issues 

4. Data Quality Concerns

• Incomplete or inconsistent reporting 

Challenges vs Impact

Outlook of Digital Pharmacovigilance

1. AI & Machine Learning

• Automated signal detection 
• Case prioritization 
• Predictive safety analytics 

Adoption is growing but still evolving.

2. Blockchain Technology

• Secure data sharing 
• Transparent audit trails 
• Enhanced regulatory compliance 

Currently in exploratory stages.

3. Interoperability & Integration

• Integration with National Health Stack 
• Linkage with ABHA (Ayushman Bharat Health Account) 
• Unified patient health records 

Enables holistic healthcare data ecosystems.

Best Practices for Stakeholders

• Strengthening reporting culture among healthcare professionals 
• Invest in digital infrastructure and training 
• Ensure data accuracy and completeness 
• Align with global pharmacovigilance standards 
• Adopt emerging technologies proactively 

Conclusion

India’s transition to digitized pharmacovigilance systems marks a significant step toward enhancing drug and vaccine safety.

While challenges such as underreporting and infrastructure gaps persist, the integration of:

• Digital platforms 
• Real-time reporting 
• Global data sharing 

is transforming India’s PV landscape.

A continued focus on technology, awareness, and regulatory alignment will ensure safer healthcare outcomes and stronger global positioning.

FAQs 

1. What is pharmacovigilance?
The science of monitoring drug safety and adverse effects.

2. What is Vigiflow used for?
It is a WHO system for managing and analyzing adverse event reports.

3. Who manages pharmacovigilance in India?
CDSCO and IPC under the PvPI program.

4. What is e-AEFI?
A digital system for tracking vaccine-related adverse events.

5. What are the main challenges in India’s PV system?
Underreporting, awareness gaps, and infrastructure limitations.

6. What is the future of pharmacovigilance in India?
AI-driven, integrated, and real-time safety monitoring systems.